Vacunas最新文献

{"title":"Vaccination impact on long COVID sequelae; a perspective view","authors":"Farhad Dadgar , Fatemeh Dehghani , Farzaneh Peikfalak , Masoud Keikha","doi":"10.1016/j.vacun.2023.06.007","DOIUrl":"10.1016/j.vacun.2023.06.007","url":null,"abstract":"","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":"25 1","pages":"Pages 147-148"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43508126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Variantes genéticas rs1800629 en TNF y rs2228145 en IL6R: asociación con eventos supuestamente atribuibles a la vacunación e inmunización (ESAVI) y anticuerpos neutralizantes contra SARS-CoV-2 en la población del occidente de México vacunada con AZD1222","authors":"Axel Jair Villa-Panduro ,&nbsp;Narda M. Corona-Reynaga ,&nbsp;Dennis A. Meza-Peña ,&nbsp;Mayra Alejandra Enciso Ramírez ,&nbsp;Astrid Selene Espinoza García ,&nbsp;Jorge Galindo-García ,&nbsp;Berenice Sanchez-Caballero ,&nbsp;Elia Herminia Valdés-Miramontes ,&nbsp;José Francisco Muñoz-Valle ,&nbsp;Zyanya Reyes-Castillo","doi":"10.1016/j.vacun.2023.12.004","DOIUrl":"10.1016/j.vacun.2023.12.004","url":null,"abstract":"<div><h3>Introduction</h3><p>In this research, we evaluated the association of genetic variants rs1800629 in <em>TNF</em> and rs2228145 in <em>IL6R</em> with production of neutralizing antibodies against SARS-CoV-2 and the frequency of adverse effects following immunization (AEFIs) in adult population from Western of Mexico that received AZD1222 vaccination.</p></div><div><h3>Methods</h3><p>One hundred-seventeen adults were evaluated (33 years [23-40], 65% women). The self-reported frequency of AEFIs was recorded and the percentage of post-vaccination neutralizing antibodies was quantified. The identification of rs1800629 variant in <em>TNF</em> and rs2228145 in <em>IL6R</em> was performed by qPCR.</p></div><div><h3>Results</h3><p>The genotype frequencies of rs1800629 variant were: GG (86%) and GA (14%), and for rs2228145 variant were: AA (20%), CA (48%) and CC (32%). The percentage of post-vaccination antibodies was similar between men and women (median, 97.24%). An association was found between the frequency of AEFIs with the sex; being adynamia (<em>p</em> <!-->=<!--> <!-->0.0243), chills (<em>p</em> <!-->=<!--> <!-->0.0085), arthralgia (<em>p</em> <!-->=<!--> <!-->0.0227) and pain in application area (<em>p</em> <!-->=<!--> <!-->0.0096) more frequent in women. The GA genotype of rs1800629 variant showed an association with fever (<em>p</em> <!-->=<!--> <!-->0.0131) and arthralgia (<em>p</em> <!-->=<!--> <!-->0.0058) post-vaccination, but no relationship was found with the production of neutralizing antibodies after AZD1222 vaccination. The rs2228145 variant was not associated with the production of antibodies nor with the AEFIs reported.</p></div><div><h3>Conclusion</h3><p>The genetic variants rs1800629 in <em>TNF</em> and rs222815 in <em>IL6R</em> are not associated with the production of neutralizing antibodies against SARS-CoV-2 after receiving AZD1222 scheme in population from western of Mexico; however, the results suggest that rs1800629 variant increases the frequency of post-vaccination events, particularly fever and arthralgia.</p></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":"25 1","pages":"Pages 78-87"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139639564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Situación actual de las vacunas atenuadas intranasales frente al virus respiratorio sincitial en la población infantil","authors":"Jordi Reina ,&nbsp;Andrés Suárez","doi":"10.1016/j.vacun.2023.12.001","DOIUrl":"10.1016/j.vacun.2023.12.001","url":null,"abstract":"<div><p>The respiratory syncytial virus (RSV) is the cause of acute respiratory pathologies (bronchiolitis and pneumonia), which occur preferably in the pediatric population in an epidemic manner. The only way to prevent these infections is through prior vaccination of children older than<!--> <!-->6 months. Of the different existing vaccines, attenuated vaccines, defined as those that contain an altered or modified virus to minimize its pathogenic capacity while maintaining its immunological response capacity, seem to represent an important advance. In recent years, two vaccine candidates based on the M2-2 gene deletion have been evaluated, those designated MEDI/ΔM2 and LID/ΔM2-2/1030s. In the study carried out in 21 seronegative children (6-24 months), they received an intranasal dose (10⁵ PFU) of the new vaccine compared to a placebo group. Eighty-five percent of those vaccinated developed a neutralizing antibody titer <!--> <!-->4 times greater than the previous one. The combination of the Δ1313 deletion with the NS2 deletion was shown to be better for the development of an attenuated RSV recombinant vaccine candidate (ΔNS2/Δ1313), with good protective results. A new vaccine candidate designated RSV/6120/ΔNS2/1030s was developed that is identical to the previous virus RSV/ΔNS2/Δ1313/I1314L but with additional mutations. Finally, a RSV with a single replicative cycle has been developed by eliminating the gene encoding the matrix (M) protein (RSV-M-null). Most of these vaccines are still in phase 2/3 and very good results are expected.</p></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":"25 1","pages":"Pages 140-146"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139456763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"La ampliación de criterios de administración de palivizumab no disminuye los ingresos por virus respiratorio sincitial","authors":"Jessica Gómez Ávila,&nbsp;Juan Iñigo Gil,&nbsp;Beatriz Flores Méndez","doi":"10.1016/j.vacun.2023.10.007","DOIUrl":"10.1016/j.vacun.2023.10.007","url":null,"abstract":"<div><h3>Introduction</h3><p>Respiratory syncytial virus is the leading cause of hospital admission for bronchiolitis in Spain. Immunoprophylaxis with palivizumab is an effective measure in those patients who meet the criteria for its administration. The aim of our study was to evaluate whether the extension of these criteria would reduce the rate of hospitalisation for this reason.</p></div><div><h3>Methods</h3><p>A retrospective analytical observational case-control study was conducted in a tertiary hospital, including 338 neonates born between 2017 and 2022. The “controls” arm included patients with criteria for palivizumab administration according to the Spanish Society of Neonatology indications, and the “cases\" arm included preterm patients up to 35 weeks of gestational age excluded from these criteria. The main variables assessed were the occurrence of respiratory syncytial virus bronchiolitis and the need for admission in both groups.</p></div><div><h3>Results</h3><p>The incidence of RSV bronchiolitis and admission to the hospital ward in the case group was similar to that found in our palivizumab-immunised population (control group).</p><p>Statistically significant differences were only found for the presence of school-aged siblings as a risk factor for the development of bronchiolitis.</p></div><div><h3>Conclusions</h3><p>An extension of the criteria for palivizumab administration to all preterm infants younger than 35 weeks would lead to increased costs without a reduction in infection rates and respiratory syncytial virus admissions.</p></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":"25 1","pages":"Pages 71-77"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139296009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prevalence of post-COVID-19 vaccination syndrome and quality of life among COVID-19-vaccinated individuals","authors":"Yogendra Shrestha,&nbsp;Rajesh Venkataraman","doi":"10.1016/j.vacun.2023.10.002","DOIUrl":"10.1016/j.vacun.2023.10.002","url":null,"abstract":"<div><h3>Background</h3><p><span>There were many studies conducted to determine how immunization affects people with long-term COVID. The results of those studies have caused debate as they gave rise to varying outcomes. Some evidence indicates a change in, an improvement in, a continuation of, or even a worsening of long-term COVID symptoms following vaccination. The ratio of change in antibody titers was noticeably larger in the group of people whose illnesses became worse. Hence, this study aimed to explore potential post-COVID-19 vaccination syndrome (PCVS) in vaccinated individuals and also to assess their </span>quality of life (QoL).</p></div><div><h3>Methodology</h3><p>Between September 2021 and May 2023, an ambidirectional, descriptive, follow-up cohort study was conducted, enrolling participants who were 18 years of age or older, met the vaccination requirements established by the Ministry of Health and Family Welfare, Government of India, and had completed the primary immunization series with the AZD1222® or BBV152® vaccine. The prevalence of PCVS and the QoL measured using EQ-5D-5L were assessed at 1 month, 6 months, and 12 months post-COVID-19 vaccination.</p></div><div><h3>Results</h3><p>AZD1222® vaccine was received by 84.28% (343) of the participants, and BBV152® vaccine was received by 15.72% (64) of the study participants. <em>A month after the primary vaccination series</em>, 52.8% (215) of the total participants had at least 1 PCVS, 39.8% (162) at 6 months, and 64.6% (263) at 12 months. Among those who had received vaccinations, the QoL increased at 6 months to 0.975<!--> <!-->±<!--> <!-->0.08 and declined at 12 months to 0.94<!--> <!-->±<!--> <!-->0.13 from 0.949<!--> <!-->±<!--> <!-->0.13 at 1 month after receiving a primary immunization. The overall prevalence of PCVS between AZD1222®-vaccinated individuals and BBV152®-vaccinated individuals at a month post-vaccination was 54.5% vs. 43.8%, at 6 months it was 41.1% vs. 32.8%, and at 12 months it was 65.59% vs. 59.4%. The QoL between AZD1222®-vaccinated individuals and BBV152®-vaccinated individuals at a month post-vaccination was 0.95<!--> <!-->±<!--> <!-->0.13 vs. 0.95<!--> <!-->±<!--> <!-->0.126, at 6 months it was 0.98<!--> <!-->±<!--> <!-->0.08 vs. 0.97<!--> <!-->±<!--> <!-->0.07, and at 12 months it was 0.94<!--> <!-->±<!--> <!-->0.12 vs. 0.92<!--> <!-->±<!--> <!-->0.20. However, there was no statistically significant difference in the prevalence of PCVS and QoL between AZD1222® and BBV152®-vaccinated individuals.</p><p><span>The percentage of participants who had at least one PCVS was 83.9% (146) in the group that got booster doses and 50.2% (117) in the group that did not. The QoL was 0.9</span> <!-->±<!--> <!-->0.15 in the group receiving booster dosages and 0.96<!--> <!-->±<!--> <!-->0.11 in the group not receiving them. There was a statistically significant difference in the prevalence of PCVS and QoL between booster dose recipients and no booster dose recipients.<","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":"25 1","pages":"Pages 7-18"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135614149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the psychological impact of anxiety, depression, and quality of life in patients with comorbid disease conditions post COVID-19 pandemic era","authors":"Anmar Al-Taie Dr. PhD ,&nbsp;Dania A. Mohd Khalaf ,&nbsp;Oritsetimeyin Arueyingho","doi":"10.1016/j.vacun.2023.08.005","DOIUrl":"10.1016/j.vacun.2023.08.005","url":null,"abstract":"<div><h3>Background</h3><p><span>Chronic diseases and comorbidity are important predictors of depression and anxiety, the two most common disorders of poor mental health. Meanwhile, the pandemic increases anxiety and depression levels, alongside declined </span>quality of life (QoL), the same way that comorbidities are associated with severity of COVID-19 progression. This study aimed to assess the prevalence of anxiety and depression, as well as the QoL among patients with chronic medical conditions in Amman, Jordan, in the post-pandemic period.</p></div><div><h3>Methods</h3><p>A descriptive, cross-sectional study was conducted among patients with comorbidities using a validated questionnaire consisting of 3 parts. Anxiety and depression prevalence were assessed using the Hospital Anxiety and Depression Scale (HADS), while the QoL in terms of physical, psychological, social, emotional, and general mental health was evaluated using the SF-36 QoL questionnaire.</p></div><div><h3>Results</h3><p>A total of 150 participants (mean age<!--> <!-->=<!--> <!-->55<!--> <!-->±<!--> <!-->13 years) were enrolled in the study. Most participants reported a significantly elevated level of borderline abnormal or mild anxiety (44%, <em>P</em> <!-->&lt;<!--> <!-->.0001). The QoL scores indicated relatively poor well-being, particularly in the physical role (29.2<!--> <!-->±<!--> <!-->45.5) and emotional role (26.2<!--> <!-->±<!--> <!-->4.0) domains (<em>P</em> <!-->&lt;<!--> <span>.05). Statistical significance was observed between HADS anxiety or depression scores and variables, such as age, education level, and comorbidities.</span></p></div><div><h3>Conclusion</h3><p>This study's findings provide insights into the adverse psychiatric consequences, high prevalence of anxiety and depressive symptoms, and reduced quality of life among patients with comorbid conditions post-COVID-19 pandemic.</p></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":"25 1","pages":"Pages 46-53"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138988581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Simultaneous detection and genomic characterization of Zika virus Protein M, E and NS1 using optimized primers from Asian and African Lineage","authors":"Muhammed Mustapha Suleiman ,&nbsp;Olatunji Matthew Kolawole","doi":"10.1016/j.vacun.2023.07.003","DOIUrl":"10.1016/j.vacun.2023.07.003","url":null,"abstract":"<div><h3>Purpose</h3><p>Despite positive serological outcome, molecular confirmations have encountered little/no success either due to protocol accuracy, primer targets, or choice of sample amongst others. This study aims at providing an optimized protocol for the molecular detection of Zika virus amongst serologically positive respondent using samples from 2 selected hospitals in North Central Nigeria.</p></div><div><h3>Materials and methods</h3><p>About five (5) ml of blood samples was collected from a total of 400 participants for serological analysis, the IgM-positive samples were processed for molecular analysis using target primers from Asian and African lineage while a structured questionnaire was used to evaluate risk factors.</p></div><div><h3>Results</h3><p>Prevalence of 19% (38) and 45% (90) IgM and IgG positivity was recorded amongst respondent in Federal Medical Center (FMC), Keffi (R² <!-->=<!--> <!-->1) while 36% (72) and 42% (84) was recorded in General Hospital (GH), Minna (R² <!-->=<!--> <!-->1). The respective risk factors such as proximity of respondent to stagnant water or drainage channel, frequency of mosquito bite, prevention strategy, implementation of the prevention strategies for mosquito, and consumption of bushmeat were significant at set standard of <em>P</em> <!-->&lt;<!--> <!-->0.05. Molecular quantification revealed cut-off values (Ct) from 21.73 to 25.75 for all the 3 targeted protein while sequence analysis showed relatedness to deposited sequences in GenBank.</p></div><div><h3>Conclusions</h3><p>The abundance of the viral proteins as well as the genetic relatedness is indicative of presence of multiple strains of the virus or conservation of region across different geolocations. In lieu of the outcome, primers from multiple lineages is thereby recommended to forestall/overcome the challenge of cross-reactivity/false-negativity with Zika virus detection.</p></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":"25 1","pages":"Pages 40-45"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135249314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 vaccines, perceptions and trust amongst vaccine refusers: A qualitative thematic analysis study","authors":"Deldar Morad Abdulah ,&nbsp;Hawar Abdulrazaq Mohammedsadiq ,&nbsp;Pranee Liamputtong","doi":"10.1016/j.vacun.2023.06.010","DOIUrl":"10.1016/j.vacun.2023.06.010","url":null,"abstract":"<div><h3>Background</h3><p>The outbreak of coronavirus disease 2019 (COVID-19) has resulted in huge morbidity and mortality since its onset in 2019. By June 24, 2023, only 32.2% of people in low-income countries have received at least one dose. This paper explores the perceptions and trust of vaccine refusers based on the thematic analysis.</p></div><div><h3>Methods</h3><p>In this study, we used a descriptive qualitative research design to explore the perceptions of the persons who did not believe in receiving the COVID-19 vaccine in Iraqi Kurdistan. This approach allowed us to explore the COVID-19 vaccine issue in-depth. Individual interviews were conducted with 14 participants in Kurdistan, Iraq.</p></div><div><h3>Results</h3><p>Results showed that the participants had a great fear of the serious side effects of COVID-19 vaccines. Some believed that the virus was not natural and had been made by humans for different reasons including making profits from vaccines. Some believed that there was a silver material inside the vaccine that would force people to receive more doses in the future. Few believed that receiving COVID-19 vaccines was crossing the borders of God. Reinfection was a factor in selling more doses of vaccines. The participants were affected by the advice of the community and social media and not receiving the COVID-19 vaccines from healthcare workers, lack of responsibility from the government and companies, and not having trust in vaccines in this region.</p></div><div><h3>Conclusions</h3><p>Conspiracy thinking, perceived negative effects, fear, reinfection, side effects of COVID-19 vaccines could be related to perceived vulnerability and seriousness among vaccine refusers.</p></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":"25 1","pages":"Pages 19-29"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46636402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of HCV among patients with HIV in Iran: A systematic review and meta-analysis","authors":"Maedeh Hajizadeh ,&nbsp;Maryam Moradi Binabaj ,&nbsp;Arezoo Asadi ,&nbsp;Milad Abdi ,&nbsp;Abolfazl Shakiba ,&nbsp;Masoumeh Beig ,&nbsp;Mohsen Heidary ,&nbsp;Mohammad Sholeh","doi":"10.1016/j.vacun.2023.08.003","DOIUrl":"10.1016/j.vacun.2023.08.003","url":null,"abstract":"<div><h3>Background</h3><p><span>Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections are major </span>public health issues worldwide. The present study aimed to estimate the prevalence of HCV among patients with HIV in Iran and evaluate the demographic and behavioral factors associated with a heterogeneity of results.</p></div><div><h3>Methods</h3><p><span>MEDLINE (via PubMed), Web of Science, SCOPUS, Google Scholar, Embase, and 2 Persian databases, including Scientific Information Database (SID) and Magiran, were used for a systematic search from January 1, 2005 to February 26, 2022. Data were analyzed according to country, publication time, enrolment time, number of patients, gender, mean age, HIV/HCV diagnosis method, and HIV/HCV </span>treatment. The analysis was carried out using R and the metafor package.</p></div><div><h3>Results</h3><p>We found that 60.94 (95% CI 54.59–67.11) HIV-infected people in Iran were co-infected with HCV. The greatest burden of this co-infection was in the Hamedan 86.67 (62.12, 96.26), Kashan 85.71 (75.03, 92.30), followed by the Kerman 73.94(66.75, 80.04). The lowest prevalence of HBV-HCV co-infection was observed in Kermanshah at 11.91 (9.98, 13.98).</p></div><div><h3>Conclusion</h3><p><span>HBV-HCV co-infection is a challenging and important medical condition because of its variable clinical manifestations, increased risk of cirrhosis and HCC, and unpredictable treatment response. Due to the heterogeneous distribution pattern of HBV–HCV infection in Iran, continuous prevention and control measurements and the implementation of further </span>epidemiologic studies are necessary.</p></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":"25 1","pages":"Pages 128-139"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138616774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Attitudes and concerns of Turkish nursing students against the COVID-19 vaccine, willingness to be vaccinated: A cross-sectional study","authors":"Zeynep Daşıkan ,&nbsp;Mashood Katuntu Waiswa","doi":"10.1016/j.vacun.2023.07.001","DOIUrl":"10.1016/j.vacun.2023.07.001","url":null,"abstract":"<div><h3>Introduction</h3><p>This study aimed to determine the attitudes and concerns of nursing students toward the coronavirus disease-2019 (COVID-19) vaccine, their willingness to be vaccinated, and the factors affecting their willingness in the second wave of the COVID-19 pandemic.</p></div><div><h3>Method</h3><p>This cross-sectional study was conducted using an online questionnaire in 498 nursing students in Izmir. Chi-square test, Student’s <em>t</em><span>-test and binary logistic regression were used in data analysis.</span></p></div><div><h3>Results</h3><p><span>Despite the fact that 64.5% of nursing students intended to be vaccinated against COVID-19, they expressed their attitudes and concerns about the lack of COVID-19 vaccination information (65.7%), its effectiveness (41.6%), and safety (45.8%). Students did not intend to be vaccinated due to insufficient trust in the vaccine effectiveness (84%), the continuous COVID-19 mutation. Strong predictors of nursing students' intention to be vaccinated in the logistic regression analysis; education level, family income perception, history of vaccination rejection in the past, confidence in the vaccine, the effectiveness of the vaccine, the side effects of the vaccine, seeing oneself as a guinea pig, and thinking that the vaccine will change the genetic structure were determined (p</span> <!-->&lt;<!--> <!-->0.05).</p></div><div><h3>Conclusion</h3><p>Nursing students are known to be future healthcare professionals and play a decisive role in counseling individuals in the community on the risks of COVID-19 and the benefits of the vaccine. Therefore, focusing on training that is aimed at increasing vaccine knowledge, eliminating their negative attitudes and concerns, and building confidence in vaccines is necessary.</p></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":"25 1","pages":"Pages 30-39"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134976778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}